SC PHARMA CONSULTING LIMITED
Company number 13609314 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
SONALI PHARMA LIMITED - Analysis Report
Company Number: 13609314
Analysis Date: 2025-07-29 20:41 UTC
Risk Rating: HIGH
Justification: The company shows a marked deterioration in net assets from £4,130 in 2023 to only £137 in 2024, indicating severe erosion of equity. Current assets have decreased while current liabilities increased, substantially reducing net current assets and working capital. This signals potential solvency and liquidity stress in a very small company.Key Concerns:
- Eroding Net Assets: The decline from £4,130 to £137 net assets within one year is a significant red flag for solvency risk.
- Low Working Capital: Net current assets dropped from £5,630 to £1,601, restricting the company’s ability to meet short-term obligations.
- Single Director and Employee: The company relies solely on one director/employee, which may pose operational and governance risks.
- Positive Indicators:
- Compliance: All statutory filings (accounts, confirmation statements) are up to date with no overdue submissions, indicating regulatory compliance.
- Clear Ownership and Control: Sole control by Mrs. Sonali Cheema with 75-100% shareholding and voting rights reduces complexity in decision-making.
- Micro-Entity Status: Small scale may limit exposure to large liabilities and overheads.
- Due Diligence Notes:
- Investigate the causes behind the sharp decline in net assets and working capital, including any large liabilities or impairments.
- Review cash flow statements to assess liquidity and operational cash generation capacity.
- Assess any contingent liabilities or related party transactions not visible in the balance sheet.
- Explore business model viability given reliance on a single individual and limited scale.
- Confirm whether the company has any external financing arrangements or guarantees.
Sign in to generate a free AI analysis of this company — no password needed, just an email link.